HIGHLIGHTS January to September 2005

• Revenue for the third quarter amounted to € 15.0 million (€ 10.9 million), representing 38 percent revenue growth versus the corresponding period last year. Excluding the acquisition effect, the growth was 33 percent. • Revenue for the nine months amounted to € 42.4 million, representing 38 percent growth versus last year. Excluding the acquisition effect, the growth was 34 percent. • Constant currency growth versus last year for the first 9 months amounted to 26 percent, up from 18 percent for the same period last year and excluding acquisitions was 23 percent (14 percent). • During the third quarter we increased our member base by 8,500 members versus 5,800 for the same period last year. Member growth for the 9 months amounted to 33,900, more than double last year’s 15,400 new members for the same period. Our total member base by end of the third quarter was 173,800, representing member growth of 31 percent versus last year. • The laboratory division continued to report strong growth with third quarter revenue of € 3.1 million and € 8.7 million for the 9 months (excluding inter-segment revenue), an increase of 36 percent and 47 percent respectively versus last year, of which 12 percent and 25 percent was organic growth. • The operating profit (EBIT) for the third quarter was € 0.6 million versus last year’s break-even for the comparable period, and for the first nine months € 1.5 million versus a loss of € 0.3 million for the prior year period. • The operating profit before depreciation and amortization (EBITDA) amounted to € 1.6 million or 10.7 percent of revenue for the third quarter (€ 0.8 million or 7.6 percent of revenue) and to € 4.1 million or 9.6 percent of revenue for the nine months (€ 2.1 million or 6.9 percent of revenue). • The profit after tax for the third quarter amounted to € 0.4 million (loss € 0.1 million) and to € 0.5 million for the nine months (loss € 0.8 million). The profit per share was € 0.031 for the quarter (loss € 0.009) and € 0.040 (loss € 0.067) for the nine months. • Net cash inflow from operating activities after tax payments was € 0.6 million for the quarter (inflow of € 1.0 million) and € 2.3 million for the nine months (inflow € 2.1 million). For further information please contact Fredrik Ragmark – Managing Director, Medicover 00 32 475 75 19 64 Joe Ryan – Finance Director, Medicover 00 32 477 56 03 82